We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
76 hedge funds and large institutions have $90.4M invested in Crescent Biopharma in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
20% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 25
0.05% less ownership
Funds ownership: 0.96% → 0.91% (-0.05%)
3% less funds holding
Funds holding: 78 → 76 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
59% less capital invested
Capital invested by funds: $220M → $90.4M (-$129M)
86% less call options, than puts
Call options by funds: $2K | Put options by funds: $14K
Holders
76
Holders Change
-2
Holders Change %
-2.56%
% of All Funds
1.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
30
Reduced
25
Closed
12
Calls
$2K
Puts
$14K
Net Calls
-$12K
Net Calls Change
-$47K
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.3M |
| 2 |
Renaissance Technologies
New York
|
+$1.24M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.17M |
| 4 |
Morgan Stanley
New York
|
+$790K |
| 5 |
Walleye Capital
New York
|
+$649K |
Top Sellers
| 1 |
Invesco
Atlanta,
Georgia
|
-$9.11M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$4.17M |
| 3 |
Axa
Paris,
France
|
-$3.5M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$704K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$577K |
